Molecular Oncology (Oct 2021)

MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary

  • Noemi Laprovitera,
  • Mattia Riefolo,
  • Elisa Porcellini,
  • Giorgio Durante,
  • Ingrid Garajova,
  • Francesco Vasuri,
  • Ariane Aigelsreiter,
  • Nadia Dandachi,
  • Giuseppe Benvenuto,
  • Federico Agostinis,
  • Silvia Sabbioni,
  • Ioana Berindan Neagoe,
  • Chiara Romualdi,
  • Andrea Ardizzoni,
  • Davide Trerè,
  • Martin Pichler,
  • Antonietta D'Errico,
  • Manuela Ferracin

DOI
https://doi.org/10.1002/1878-0261.13026
Journal volume & issue
Vol. 15, no. 10
pp. 2732 – 2751

Abstract

Read online

Metastasis is responsible for the majority of cancer‐related deaths. Particularly, challenging is the management of metastatic cancer of unknown primary site (CUP), whose tissue of origin (TOO) remains undetermined even after extensive investigations and whose therapy is rather unspecific and poorly effective. Molecular approaches to identify the most probable TOO of CUPs can overcome some of these issues. In this study, we applied a predetermined set of 89 microRNAs (miRNAs) to infer the TOO of 53 metastatic cancers of unknown or uncertain origin. The miRNA expression was assessed with droplet digital PCR in 159 samples, including primary tumors from 17 tumor classes (reference set) and metastases of known and unknown origin (test set). We combined two different statistical models for class prediction to obtain the most probable TOOs: the nearest shrunken centroids approach of Prediction Analysis of Microarrays (PAMR) and the least absolute shrinkage and selection operator (LASSO) models. The molecular test was successful for all formalin‐fixed paraffin‐embedded samples and provided a TOO identification within 1 week from the biopsy procedure. The most frequently predicted origins were gastrointestinal, pancreas, breast, lung, and bile duct. The assay was applied also to multiple metastases from the same CUP, collected from different metastatic sites: The predictions showed a strong agreement, intrinsically validating our assay. The final CUPs' TOO prediction was compared with the clinicopathological hypothesis of primary site. Moreover, a panel of 13 miRNAs proved to have prognostic value and be associated with overall survival in CUP patients. Our study demonstrated that miRNA expression profiling in CUP samples could be employed as diagnostic and prognostic test. Our molecular analysis can be performed on request, concomitantly with standard diagnostic workup and in association with genetic profiling, to offer valuable indications about the possible primary site, thereby supporting treatment decisions.

Keywords